PDCD1 and cancer: Vaccination of patients with anti programmed cell death protein 1 (anti-PD-1)/PD-L1 therapy has been widely debated, but there are studies that have shown that cancer treatment can be maintained if there is a window period of more than 16 days between the first dose of the vaccine and the first dose of the drug, with no impact in effectiveness or side effects [80].